Nicole A. Doria‐Rose
A5085482528- HIV Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS drug development and treatment
- T-cell and B-cell Immunology
- vaccines and immunoinformatics approaches
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- Animal Virus Infections Studies
- HIV/AIDS Research and Interventions
- COVID-19 Clinical Research Studies
- Cytomegalovirus and herpesvirus research
- Viral gastroenteritis research and epidemiology
- Herpesvirus Infections and Treatments
- SARS-CoV-2 detection and testing
- Blood groups and transfusion
- RNA and protein synthesis mechanisms
- Influenza Virus Research Studies
- Hepatitis B Virus Studies
- Viral Infections and Immunology Research
- Virus-based gene therapy research
- Bacteriophages and microbial interactions
- Vaccine Coverage and Hesitancy
- Enzyme Structure and Function
National Institute of Allergy and Infectious Diseases
2016-2025
National Institutes of Health
2016-2025
New York Academy of Sciences
2023
John Wiley & Sons (Germany)
2023
Moss Landing Marine Laboratories
2023
Hudson Institute
2023
Kaiser Permanente
2020
Children's Healthcare of Atlanta
2020
University of Maryland, Baltimore
2020
Emory University
2020
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. We conducted phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 55 years age, who received two vaccinations, 28 days apart, with dose 25 μg, 100 or 250 μg. There were 15 participants each group. After...
Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1-infected individuals, but virologic basis their neutralization remains poorly understood. We used knowledge HIV-1 envelope structure to develop antigenically resurfaced glycoproteins specific for structurally conserved site initial CD4 receptor binding. These probes were identify with NAbs CD4-binding (CD4bs) and isolate individual B cells from such an donor. By expressing immunoglobulin genes cells, we...
Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences illness and death from disease 2019 (Covid-19) have been associated age. We conducted a phase 1, dose-escalation, open-label trial messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) healthy adults. The was expanded include 40 adults, who were stratified...
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important evaluate nonhuman primates. Nonhuman primates received 10 or 100 μg mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein SARS-CoV-2, no vaccine. Antibody T-cell responses were assessed before upper- lower-airway challenge with SARS-CoV-2. Active genomes...
Broadly neutralizing antibodies to HIV with similar specificities can be found in multiple HIV-infected individuals.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, angiotensin-converting enzyme (ACE2)–competing antibodies elicited by messenger RNA (mRNA) vaccine mRNA-1273 7 months. Cross-reactive...
The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention treatment HIV infection. We sought to determine whether administration VRC01, bNAb targeting CD4-binding site, can safely prevent or delay plasma viral rebound after discontinuation antiretroviral therapy (ART).
Antibodies block Ebola virus entry The recent outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of 1995 Kikwit demonstrated their therapeutic efficacy virus–infected macaques. In fact, one antibody protected macaques when it was given up 5 days after infection. Misasi solved crystal structures fragments bound glycoprotein (GP), which mediates viral cell entry....
An antibody to block viral fusion A small fraction of HIV-1–infected individuals develop broad and potent antibodies that bind the HIV-1 envelope protein (Env). These recognize a limited set conserved epitopes on Env, such as Env's host receptor-binding site. Kong et al. now report neutralizing isolated from an individual binds peptide Env. This is unexpected because viruses often try mask key components their cell entry machinery attack. Crystal structures bound Env itself define epitope,...
ABSTRACT Induction of broadly cross-reactive neutralizing antibodies (NAb) is an important goal for a prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine. Some HIV-infected patients make NAb response that reacts with diverse strains HIV-1, but most candidate vaccines have induced only against subset highly sensitive isolates. To better understand the nature broad responses arise during natural infection, we screened sera able to neutralize HIV and explored frequency phenotype...
ABSTRACT Induction of antibodies that neutralize a broad range human immunodeficiency virus type 1 (HIV-1) isolates is major goal vaccine development. To study natural examples neutralization, we analyzed sera from 103 HIV-1-infected subjects. Among progressor patients, 20% neutralized more than 75% panel 20 diverse viral isolates. Little activity was observed in long-term nonprogressors (elite controllers). Breadth neutralization correlated with load, but not CD4 count, history past...
Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1 antibodies has been identified. These can protect against lentiviral infection in nonhuman primates (NHPs), suggesting that passive antibody transfer would prevent transmission humans. To increase protective efficacy such monoclonal antibodies, we employed next-generation sequencing, computational bioinformatics, structure-guided design to enhance neutralization potency breadth VRC01, an targets CD4...
The development of an effective AIDS vaccine has been challenging because viral genetic diversity and the difficulty generating broadly neutralizing antibodies (bnAbs). We engineered trispecific (Abs) that allow a single molecule to interact with three independent HIV-1 envelope determinants: CD4 binding site, membrane-proximal external region (MPER), V1V2 glycan site. Trispecific Abs exhibited higher potency breadth than any previously described bnAb, showed pharmacokinetics similar those...
ABSTRACT The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable templates for vaccine design, and studies of the immunological development these providing insights vaccination strategies. In addition, most potent reactive bNAbs have potential clinical use. We previously described a family 12 V1V2-directed antibodies, CAP256-VRC26, isolated from an clade C-infected donor at years 1, 2, 4 infection (N. A. Doria-Rose et al., Nature 509:55–62, 2014,...